NDA 6317, held by Lilly. Sulfadiazine; Sulfamerazine, Trisulfapyrimidines (Sulfadiazine;Sulfamerazine;Sulfamethazine).
As of Nov 13, 2026, NDA 6317 (Sulfonamides Duplex, Neotrizine), held by Lilly, was not approved, with 0 approved supplements and 0 published complete response letters.
| Sulfonamides Duplex250MG/5ML;250MG/5ML · suspension;oral | Sulfadiazine; Sulfamerazine | Discontinued |
| Neotrizine167MG;167MG;167MG · tablet;oral | Trisulfapyrimidines (Sulfadiazine;Sulfamerazine;Sulfamethazine) | Discontinued |
| Neotrizine167MG/5ML;167MG/5ML;167MG/5ML · suspension;oral | Trisulfapyrimidines (Sulfadiazine;Sulfamerazine;Sulfamethazine) | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
